No Cover Image

Journal article 728 views 152 downloads

Recent advances in understanding the role of glucagon-like peptide 1

Josh Reed, Steve Bain Orcid Logo, Venkat Kanamarlapudi Orcid Logo

F1000Research, Volume: 9, Start page: 239

Swansea University Authors: Steve Bain Orcid Logo, Venkat Kanamarlapudi Orcid Logo

  • 54102.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution License (CC-BY).

    Download (4.96MB)

Check full text

DOI (Published version): 10.12688/f1000research.20602.1

Abstract

The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment ba...

Full description

Published in: F1000Research
ISSN: 2046-1402
Published: F1000 Research Ltd 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa54102
first_indexed 2020-05-01T19:38:40Z
last_indexed 2020-10-21T03:05:57Z
id cronfa54102
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-10-20T15:43:19.1726167</datestamp><bib-version>v2</bib-version><id>54102</id><entry>2020-05-01</entry><title>Recent advances in understanding the role of glucagon-like peptide 1</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>63741801137148abfa4c00cd547dcdfa</sid><ORCID>0000-0002-8739-1483</ORCID><firstname>Venkat</firstname><surname>Kanamarlapudi</surname><name>Venkat Kanamarlapudi</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-05-01</date><deptcode>MEDS</deptcode><abstract>The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1-based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson's disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic-based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases.</abstract><type>Journal Article</type><journal>F1000Research</journal><volume>9</volume><paginationStart>239</paginationStart><publisher>F1000 Research Ltd</publisher><issnElectronic>2046-1402</issnElectronic><keywords>GLP-1, Type 2 diabetes, incretin, GLP-1R</keywords><publishedDay>15</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-04-15</publishedDate><doi>10.12688/f1000research.20602.1</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-10-20T15:43:19.1726167</lastEdited><Created>2020-05-01T13:22:49.6911271</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Josh</firstname><surname>Reed</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author><author><firstname>Venkat</firstname><surname>Kanamarlapudi</surname><orcid>0000-0002-8739-1483</orcid><order>3</order></author></authors><documents><document><filename>54102__17168__16ecd696db38486083067ab594353b95.pdf</filename><originalFilename>54102.pdf</originalFilename><uploaded>2020-05-01T13:26:50.5929528</uploaded><type>Output</type><contentLength>5200895</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Released under the terms of a Creative Commons Attribution License (CC-BY).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2020-10-20T15:43:19.1726167 v2 54102 2020-05-01 Recent advances in understanding the role of glucagon-like peptide 1 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 63741801137148abfa4c00cd547dcdfa 0000-0002-8739-1483 Venkat Kanamarlapudi Venkat Kanamarlapudi true false 2020-05-01 MEDS The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1-based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson's disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic-based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases. Journal Article F1000Research 9 239 F1000 Research Ltd 2046-1402 GLP-1, Type 2 diabetes, incretin, GLP-1R 15 4 2020 2020-04-15 10.12688/f1000research.20602.1 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2020-10-20T15:43:19.1726167 2020-05-01T13:22:49.6911271 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Josh Reed 1 Steve Bain 0000-0001-8519-4964 2 Venkat Kanamarlapudi 0000-0002-8739-1483 3 54102__17168__16ecd696db38486083067ab594353b95.pdf 54102.pdf 2020-05-01T13:26:50.5929528 Output 5200895 application/pdf Version of Record true Released under the terms of a Creative Commons Attribution License (CC-BY). true eng http://creativecommons.org/licenses/by/4.0/
title Recent advances in understanding the role of glucagon-like peptide 1
spellingShingle Recent advances in understanding the role of glucagon-like peptide 1
Steve Bain
Venkat Kanamarlapudi
title_short Recent advances in understanding the role of glucagon-like peptide 1
title_full Recent advances in understanding the role of glucagon-like peptide 1
title_fullStr Recent advances in understanding the role of glucagon-like peptide 1
title_full_unstemmed Recent advances in understanding the role of glucagon-like peptide 1
title_sort Recent advances in understanding the role of glucagon-like peptide 1
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
63741801137148abfa4c00cd547dcdfa
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
63741801137148abfa4c00cd547dcdfa_***_Venkat Kanamarlapudi
author Steve Bain
Venkat Kanamarlapudi
author2 Josh Reed
Steve Bain
Venkat Kanamarlapudi
format Journal article
container_title F1000Research
container_volume 9
container_start_page 239
publishDate 2020
institution Swansea University
issn 2046-1402
doi_str_mv 10.12688/f1000research.20602.1
publisher F1000 Research Ltd
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1-based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson's disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic-based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases.
published_date 2020-04-15T20:04:34Z
_version_ 1821437197779206144
score 11.047609

Similar Items